Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07379684 · ClinicalTrials.gov registry record · Phase 1
A Study of Amicidin-β Topical Solution for Patients With Surgical or Traumatic Wound Infections
A Phase 1 study of Surgical Wound Infection and Traumatic Wound Infection, sponsored by Macro Biologics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 3
- Study locations
NCT07379684 is a Phase 1 study of Surgical Wound Infection and Traumatic Wound Infection that is actively recruiting participants, run by Macro Biologics. The registered enrollment target is 44 participants, below the 923-participant average among 8 other Surgical Wound Infection trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT07379684, a Phase 1 study of Surgical Wound Infection and Traumatic Wound Infection, is actively recruiting participants, sponsored by Macro Biologics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this Phase 1 clinical trial is to learn about the safety profile of Amicidin-β topical solution applied directly into infected surgical or traumatic wounds during a surgical procedure. The main questions it aims to answer are: 1. Is Amicidin-β topical solution safe to test in larger clinical trials? 2. Is Amicidin-β topical solution absorbed into the bloodstream from local wound application? 3. Is Amicidin-β topical solution easy for the surgeon to use? Participants will receive either standard of care alone, or standard of care with intrawound Amicidin-β topical solution for the management of their wound infection. Researchers will compare these two groups (standard of care alone to standard of care with Amicidin-β topical solution) to see if there are any study drug-related adverse effects.
Conditions Studied
Interventions
- DRUG Standard of Care (SOC)
- DRUG Amicidin-β topical solution - 15 mL
- DRUG Amicidin-β topical solution - 50 mL
Study Locations (3)
Idaho
- Snake River Research, PLLC - Idaho Falls
Maryland
- LifeBridge Health - Baltimore
Ohio
- The Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2026-02-02 |
| Est. Completion | 2026-10-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07379684
The ClinicalTrials.gov registry entry for NCT07379684 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 923-participant average among 8 other Surgical Wound Infection trials with a reported enrollment target (95% lower). The listed sponsor is Macro Biologics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Surgical Wound Infection appearing as the primary indexed condition, and to 3 interventions - of which Standard of Care (SOC) is the first listed.
NCT07379684 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Idaho, Maryland, Ohio.
Frequently Asked Questions
What is clinical trial NCT07379684 about?
NCT07379684 is a clinical study titled "A Study of Amicidin-β Topical Solution for Patients With Surgical or Traumatic Wound Infections". The goal of this Phase 1 clinical trial is to learn about the safety profile of Amicidin-β topical solution applied directly into infected surgical or traumatic wounds during a surgical procedure. The main questions it aims to answer are: 1. Is Amicidin-β topical solution safe to test in larger cli...
What is the current status of trial NCT07379684?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2026-02-02. Estimated completion is 2026-10-28.
What conditions does trial NCT07379684 study?
This clinical trial studies the following conditions: Surgical Wound Infection, Traumatic Wound Infection.
What interventions are being tested in trial NCT07379684?
The interventions under investigation include: Standard of Care (SOC) (DRUG), Amicidin-β topical solution - 15 mL (DRUG), Amicidin-β topical solution - 50 mL (DRUG).
Who is sponsoring clinical trial NCT07379684?
This trial is sponsored by Macro Biologics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07379684 being conducted?
This trial has 3 study locations across Idaho, Maryland, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Surgical Wound Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effect of Bacterial Decolonization Before Skin Cancer Surgery on Infection Rate of Lower Extremity Wounds Left Open to Heal
RECRUITING · Phase 3
-
Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections
RECRUITING · Phase 3
-
Reducing Intraoperative ESKAPE Transmission Through Use of a Personal Hand Hygiene System
RECRUITING · NA
-
NPWT in Patients Undergoing Surgical Procedures for Management of GI Malignancies
ACTIVE NOT RECRUITING · Phase 2
-
Local Warming of Surgical Incisions
COMPLETED · Phase 3
-
Topical Antibiotic Prophylaxis for Eyelids
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.